Tarsus Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the. treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.
